Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06449573
Other study ID # GO 23/533
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date March 1, 2024
Est. completion date July 2024

Study information

Verified date June 2024
Source Hacettepe University
Contact Aydan Asli Aksel Uylar
Phone +90312
Email aydanaaksel@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of the study compare the cardiopulmonary parameters of individuals with asthma with healthy subjects.


Description:

It is thought that aerobic capacity of asthmatic individuals decreases due to chronic respiratory disease, especially oxygen consumption. Detailed investigation will be provided with this research.


Recruitment information / eligibility

Status Recruiting
Enrollment 15
Est. completion date July 2024
Est. primary completion date July 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - No respiratory, cardiovascular and metabolic diseases - Regular non-smoker Exclusion Criteria: - Non-consenting - Pregnant women

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Exercise capacity
cardiopulmonary exercise test used assessment of exercise capacity

Locations

Country Name City State
Turkey Hacettepe University Ankara

Sponsors (1)

Lead Sponsor Collaborator
Hacettepe University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Exercise capacity Exercise capacity will be assessed by Cardiopulmonary Exercise Test. The test will be performed on a bicycle ergometer. The test will be terminated when the target heart rate is reached or when the patient indicates that they are unable to continue the test. maximal oxygen consumption and the workload achieved will be recorded. 20 minutes
Secondary Respiratory muscle strength Inspiratory and expiratory muscle strength will be measured with a mouth pressure measuring device. Measurements will be made in a sitting position with the hip and knee at 90 degrees and the trunk upright. 8 minutes
Secondary Peripheral muscle strength It will be evaluated with a portable manual muscle strength measuring device. Muscle strength of knee extensors will be measured. The measurement will be performed with the patient sitting with his/her back unsupported and his/her hands crossed on his/her chest. 5 minutes
Secondary Grip strength It will be evaluated with a portable hand dynamometer. Measurements will be made in a sitting position with the hip and knee at 90 degrees and the trunk upright. The measurement will be performed with the arm adjacent to the side of the trunk and the forearm parallel to the ground. 3 minutes
Secondary Kinesiophobia Tampa Kinesiophobia Scale will be used. A total of 17 questions will be answered in 4-point Likert form. In total, the patient scores between 17-68. A high score indicates high kinesiophobia. 3 minutes
Secondary Quality of Life (symptoms, mood, activity limitation, environmental exposure) Asthma Quality of Life Scale will be used for the evaluation. This scale consists of 4 sub-headings including symptoms, mood, activity limitation, environmental exposure and 32 questions. Each item is scored between 1-7. The total score of the scale is calculated by averaging the scores given to the items. The higher the score, the better the quality of life. 10 minutes
See also
  Status Clinical Trial Phase
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device